Management of aggressive lymphoma after CAR T-cell therapy failure.

ABSTRACT: Several recent advances have affected the treatment landscape of diffuse large B-cell lymphoma. Chimeric antigen receptor (CAR) T-cell therapy has transformed the management of chemorefractory disease. Two randomized studies in early relapse disease have expanded the label to provide access to CAR T-cell therapy as early as second line for some patients. Despite the durable remissions that have been achieved, many patients will experience relapse. There is a growing population of patients previously treated with CAR T-cell therapy facing dismal outcomes. We review the prospective studies that inform treatment options in later lines and highlight the limited data examining outcomes with novel therapies after CAR T-cell failure. The treatment landscape is anticipated to continue to evolve wi

SUBMITTER: Nastoupil LJ 

PROVIDER: S-EPMC10727106 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature